SCHEMBL5002992

SCHEMBL5002992

Fc1ccccc1N1CCN(c2cncc(-c3cccc4ccccc34)n2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
LMNA P02545 1/20 0.51
NFKB1 P19838 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
USP2 O75604 2/20 0.47
KDM4E B2RXH2 4/20 0.43
ALDH1A1 P00352 4/20 0.43
KMT2A Q03164 2/20 0.43
HSD17B10 Q99714 2/20 0.43
MEN1 O00255 1/20 0.43
MAPK1 P28482 2/20 0.42
MAPK3 P27361 1/20 0.42
PTPN11 Q06124 1/20 0.42
PIM1 P11309 6/20 0.42
PIM3 Q86V86 4/20 0.42
PIM2 Q9P1W9 3/20 0.42
SLC29A2 Q14542 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4996244 0.89 PIM1 (0.39) MAPTSMN1; SMN2LMNANFKB1NFKB2
SCHEMBL4992085 0.84 MAPT (0.52) MAPTSMN1; SMN2LMNANFKB1NFKB2
SCHEMBL4994763 0.83 MAPT (0.49) MAPTSMN1; SMN2LMNANFKB1NFKB2
SCHEMBL4997085 0.82 MAPT (0.48) MAPTSMN1; SMN2LMNANFKB1NFKB2
SCHEMBL5003446 0.82 MAPT (0.47) MAPTSMN1; SMN2LMNANFKB1NFKB2
SCHEMBL5000611 0.80 LMNA (0.45) MAPTSMN1; SMN2LMNANPSR1KDM4E
SCHEMBL4993024 0.80 RIPK3 (0.44) MAPTSMN1; SMN2LMNANFKB1NFKB2
SCHEMBL4992191 0.79 MAPT (0.54) MAPTSMN1; SMN2LMNANFKB1NFKB2
SCHEMBL4997507 0.78 MAPK1 (0.42) MAPTSMN1; SMN2NFKB1NFKB2RELA
SCHEMBL5000701 0.78 LMNA (0.51) MAPTSMN1; SMN2LMNANFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080194574-A1 Pyrazine Derivatives As Effective Compounds Against Infectious Diseases AXXIMA PHARMACEUTICALS AG (DE) 2008-08-14 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194574-A1 Pyrazine Derivatives As Effective Compounds Against Infectious Diseases PRNP, PSEN1, PPP5C MAPT 5/4885SMN1; SMN2 896/4885LMNA 2743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.